ReGen talks Colostrinin and cognition to natural health practitioners

ReGen and Metagenics are preparing for the launch of Colostrinin with the presentation of data on the nutraceutical's potential for cognitive function before a group that could be instrumental in its success - natural health practitioners.

Related Topics

Dairy-based ingredients

Related news

ReGen reports promising first half 2006

ReGen Therapeutics has been tightening its belt to reduce costs as it prepares for commercialisation of its Colostrinin nutraceutical, but first half 2006 results indicate that prospects are good and no further share issues are planned for now.

ReGen raises Colostrinin roll-out funds

ReGen Therapeutics has raised £1.1m through a share placement to boost commercialisation of its Colostrinin nutraceutical for cognitive decline and help fund pharmaceutical development.